AstraZeneca (LON: AZN) shares may see increased investor interest as its Imfinzi and Imjudo combination therapy, alongside lenvatinib and transarterial chemoembolisation (TACE), demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (HCC) eligible for embolisation.
The EMERALD-3 Phase III trial results, announced today, indicate a potential new treatment option for a patient population with limited alternatives.
The trial’s primary endpoint, PFS, saw significant improvement compared to TACE alone. Interim analysis also revealed a trend towards improved overall survival (OS), a key secondary endpoint, suggesting a potentially significant benefit for patients. While not formally tested, data for the treatment arm evaluating the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) plus TACE versus TACE alone showed strong trends toward improved PFS and OS.
WELCOME BONUS
Trade Thousands Of Global Markets
Demo account, mobile app and multi-platform access
IG
Visit Site
Empfohlener Broker
Multi Asset Platform
The study involved using the STRIDE regimen, with or without lenvatinib, before and during TACE. This approach appears to offer a more effective strategy for managing this type of liver cancer. The trial will continue to monitor OS and other key secondary endpoints in both investigational arms.
HCC, the most common form of liver cancer, affects a large patient population. More than 200,000 patients with HCC will be eligible for embolisation in 2026. Embolisation, a standard procedure, blocks blood supply to the tumor. However, disease progression or recurrence typically occurs within six to ten months for most patients undergoing embolisation. The new treatment could address this unmet need.
Ghassan Abou-Alfa, MD, JD, MBA, PhD(hc), Attending Physician, Professor of Medicine at Memorial Sloan Kettering Cancer Center, and principal investigator in the trial stated that the dual immunotherapy with durvalumab and tremelimumab in the STRIDE regimen, represents a meaningful advance for patients with embolisation-eligible liver cancer, who currently lack systemic treatment options to keep their cancer from progressing or recurring, with a trend of improving survival.
EMERALD‑3 shows we can now significantly reduce the risk of disease progression with STRIDE as the immunotherapy backbone alongside lenvatinib and TACE.
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, emphasized that the EMERALD‑3 results show that bringing the dual immunotherapy STRIDE regimen earlier, alongside TACE and lenvatinib, can further improve outcomes in earlier‑stage liver cancer. This builds on the HIMALAYA Phase III trial data in patients with advanced, unresectable disease, where the STRIDE regimen has already demonstrated durable overall survival benefit.
The company is in discussions with global regulatory authorities and awaiting final results from the key secondary endpoints.
The safety profile for each combination was consistent with the known profiles of each medicine, and there were no new safety findings.
The positive trial results could lead to increased investor confidence in AstraZeneca, potentially driving up share prices. Regulatory approvals could serve as significant catalysts.
The company will present these data at an upcoming medical meeting and share them with global regulatory authorities. This development could lead to regulatory submissions and potential market approval, further solidifying AstraZeneca’s position in the oncology space.
Analyst Summary: Bull and Bear Cases
Bull Case:
- Statistically significant improvement in progression-free survival compared to TACE alone.
- A positive trend towards improved overall survival suggests a potential long-term benefit for patients.
- Addresses a significant unmet need in patients eligible for embolisation who often experience disease progression.
Bear Case:
- Final overall survival (OS) data is not yet available as the trial is ongoing, representing a key endpoint that is still being monitored.
- The treatment has not yet received regulatory approval, and the outcome of discussions with global authorities is uncertain.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- IG Top-tier regulation – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
